Oxidative stress and psoriasis: the effect of antitumour necrosis factor- inhibitor treatment
Oxidative stress and psoriasis: the effect of antitumour necrosis factor- inhibitor treatment
复制标题
DOI：
10.1111/bjd.12144
复制
发表时间：
2013-05-01
影响因子：
10.3
通讯作者：
Offidani, A. M.
中科院分区：
文献类型：
--
作者：
Bacchetti, T.;Campanati, A.;Offidani, A. M.
背景银屑病是一种慢性炎症性皮肤疾病，与心血管事件的高发有关。据报道，银屑病患者的血脂水平发生改变，炎症和脂质过氧化生化标志物水平升高，提示银屑病与炎症和氧化损伤之间存在关系。目的探讨肿瘤坏死因子抑制剂对银屑病患者炎症活动的调节是否与脂质代谢、氧化应激和对氧磷酶(PON)1活性改变有关。方法检测23例银屑病患者服用依那西普24周前后的血脂、脂蛋白(A)水平、炎症标志物和脂质过氧化指标的变化。在相同的受试者中，研究了血浆总抗氧化能力和PON1的活性，PON1是一种与高密度脂蛋白(HDL)相关的抗氧化剂和抗炎酶。结果依那西普治疗后银屑病患者临床症状的改善与炎症标志物[C-反应蛋白(CRP)]和脂质过氧化水平的降低以及血清抗氧化能力的增强有关。这些修饰与PON1活性的显著增加有关。银屑病患者治疗后PON1/CRP比值也显著升高。C反应蛋白和PON1活性之间的显著负相关提示PON1活性与炎症之间的关系。结论依那西普治疗可减少脂质过氧化，改善高密度脂蛋白的抗氧化和抗炎性能。
Background Psoriasis is a chronic, inflammatory skin condition associated with a high frequency of cardiovascular events. Modifications of plasma lipids, and an increase in the levels of biochemical markers of inflammation and lipid peroxidation have been reported in subjects with psoriasis, suggesting a relationship between psoriasis, inflammation and oxidative damage. Objectives To investigate whether modulation of inflammatory activity by tumour necrosis factor- inhibitors in patients with psoriasis is associated with modification of lipid profiles, oxidative stress and paraoxonase (PON)1 activity. Methods The levels of plasma lipids and lipoprotein(a), and the levels of the markers of inflammation and lipid peroxidation were evaluated in subjects with psoriasis (n=23) before and after 24weeks of treatment with etanercept. In the same subjects plasma total antioxidant capacity and the activity of PON1, an antioxidant and anti-inflammatory enzyme associated with the high-density lipoproteins (HDLs), were investigated. Results The results showed that clinical improvement in patients with psoriasis treated with etanercept is associated with a reduction in the levels of inflammatory markers [C-reactive protein (CRP)] and lipid peroxidation, and also with increased antioxidant capacity in the serum of patients with psoriasis. These modifications are associated with a significant increase in the activity of PON1. A significant increase in the PON1/CRP ratio has also been observed in patients with psoriasis after treatment. The significant inverse correlation between CRP and PON1 activity suggests a relationship between PON1 activity and inflammation. Conclusions Treatment with etanercept is associated with a reduction in lipid peroxidation and an improvement in HDL antioxidant and anti-inflammatory properties.